Charles River Laboratories International, Inc.
- Jurisdiction
United States - LEI
549300BSQ0R4UZ5KX287 - ISIN
US1598641074 (CRL )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€123.57 20.3% overvalued - Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. Read full profile
Fundamentals
- Net revenue
€3.44B - Gross margin
32.3% - EBIT
€106.21M - EBIT margin
3.1% - Net income
-€59.05M - Net margin
-1.7%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| LaPlume Joseph W | EVP, Corp Strategy & Develop |
|
|
|
|
| LaPlume Joseph W | EVP, Corp Strategy & Develop |
|
|
|
|
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| Jefferson Shreve | June 22, 2025 | $15.00K–$50.00K |
| Jefferson Shreve | June 22, 2025 | $15.00K–$50.00K |
| Robert Bresnahan | May 31, 2025 | $1.00K–$15.00K |
| Robert Bresnahan | May 8, 2025 | $15.00K–$50.00K |
| Julie Johnson | February 12, 2025 | $1.00K–$15.00K |
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| James Anderson |
|
|
|
Sell |